Screening and treatment for hepatocellular carcinoma

Gastroenterology Clinics of North America

Volumn 33, Issue 3, 2004, Pages 671-691

  Sherman, Morris ^a   Takayama, Yuji ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; COMPLEMENTARY RNA; DOXORUBICIN; EPIRUBICIN; FERRITIN ANTIBODY; IODINATED POPPYSEED OIL; NOLATREXED; SEOCALCITOL; SOMATOSTATIN; THALIDOMIDE;

ALCOHOL LIVER CIRRHOSIS; ALGORITHM; ASPIRATION BIOPSY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURGERY; CATHETER ABLATION; CHEMOEMBOLIZATION; CLINICAL TRIAL; ECHOGRAPHY; HEPATITIS B; HEPATITIS C; HIGH RISK POPULATION; HISTOLOGY; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER TRANSPLANTATION; MULTIMODALITY CANCER THERAPY; NONALCOHOLIC FATTY LIVER; REVIEW; SCREENING TEST; SEROLOGY; TREATMENT INDICATION;

ALGORITHMS; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MASS SCREENING; RISK FACTORS;

EID: 8444239690     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2004.04.012     Document Type: Review

References (96)

1. Donato F., Gelatti U., Chiesa R., Albertini A., Bucella E., Boffetta P., et al. A case-control study on family history of liver cancer as a risk factor for hepatocellular carcinoma in North Italy. Brescia HCC Study. Cancer Causes Control. 10:1999;417-421
2. Sarasin F.P., Giostra E., Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in Western patients with Child-Pugh class A cirrhosis. Am J Med. 171:1996;422-434
3. Arguedas M.R., Chen V., Eloubedi M., Fallon M.B. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol. 98:2003;679-690
4. Collier J., Krahn M., Sherman M. A cost-benefit analysis of the benefit of screening for hepatocellular carcinoma in hepatitis B carriers. Hepatology. 30:1999;481A
5. Beasley R.P., Hwang L.Y., Lin C.C., Chien C.S. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22,700 men in Taiwan. Lancet. 2:1981;1129-1133
6. Beasley R.P. Hepatitis B virus. Cancer. 61:1988;1942-1956
7. Sakuma K., Saitoh N., Kasai M., Jitsukawa H., Yoshino I., Yamaguchi M., et al. Relative risks of death due to liver disease among Japanese male adults having various statuses for hepatitis B s and e antigen/antibody in serum: a prospective study. Hepatology. 8:1988;1642-1646
8. Beasley R.P., Hwang L.Y. Epidemiology of hepatocellular carcinoma. Vyas G.N., Dienstag J.L., Hoofnagle J.H. Viral hepatitis and liver disease. 1984;209-224 Grune & Stratton, New York
9. Yu M.W., Chang H.C., Liaw Y.F., Lin S.M., Lee S.D., Liu C.J., et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst. 92:2000;1159-1164
10. Kew M.C., Macerollo P. Effect of age on the etiologic role of the hepatitis B virus in hepatocellular carcinoma in blacks. Gastroenterology. 94:1988;439-442
11. Kew M.C., Marcus R., Geddes E.W. Some characteristics of Mozambican Shangaans with primary hepatocellular cancer. S Afr Med J. 51:1977;306-309
12. Fattovich G., Brollo L., Giustina G., Noventa F., Pontisso P., Alberti A., et al. Natural history and prognostic factors for chronic hepatitis type B. Gut. 32:1991;294-298
13. Fattovich G., Giustina G., Degos F., Tremolada F., Diodati G., Almasio P., et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 2:1997;463-472
14. Bruix J., Barrera J.M., Calvet X., Ercilla G., Costa J., Sanchez-Tapias J.M., et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatitis cirrhosis. Lancet. 2:1989;1004-1006
15. Niederau C., Heintges T., Lange S., Goldmann G., Niederau C.M., Mohr L., et al. Prognosis of chronic hepatitis C: result of a large prospective cohort study. Hepatology. 28:1998;1687-1695
16. Sun C.A., Wu D.M., Lin C.C., Lu S.N., You S.L., Wang L.Y., et al. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol. 157:2003;674-682
17. Bruix J., Sherman M., Llovet J.M., Beaugrand M., Lencioni R., Burroughs A.K., et al. EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 35:2001;421-430
18. Chiesa R., Donato F., Tagger A., Favret M., Ribero M.L., Nardi G. Etiology of hepatocellular carcinoma in Italian patients with and without cirrhosis. Cancer Epidemiol Biomarkers Prev. 9:2000;213
19. Hassan M.M., Hwang L.Y., Hatten C.J., Swaim M., Li D., Abbruzzese J.L., et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology. 36:2002;1206-1213
20. Schoniger-Hekele M., Muller C., Kutilek M., Oesterreicher C., Ferenci P., Gangl A. Hepatocellular carcinoma in Austria: aetiological and clinical characteristics at presentation. Eur J Gastroenterol Hepatol. 12:2000;941-948
21. Bugianesi E., Leone N., Vanni E., Marchesini G., Brunello F., Carucci P., et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 123:2002;134-140
22. Francanzani A.L., Conte D., Fraquelli M., Taioli E., Mattioli M., Lasco A., et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched controls patients with noniron-related chronic liver disease. Hepatology. 33:2001;647-651
23. Hsing A.W., McLaughlin J.K., Olsen J.H., Mellemkjar L., Wacholder S., Fraumeni J.F. Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark. Int J Cancer. 60:1995;160-162
24. Eriksson S., Carlson J., Velez R. Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. N Engl J Med. 314:1986;736-739
25. Zhou H., Fischer H.P. Liver carcinoma in PiZ alpha-1-antitrypsin deficiency. Am J Surg Pathol. 22:1998;742-748
26. Farinati F., Floreani A., DeMaria N., Fagiuoli S., Naccarato R., Chiaramonte M. Hepatocellular carcinoma in primary biliary cirrhosis. J Hepatol. 21:1994;315-316
27. Niederau C., Heintges T., Lange S., Goldmann G., Niederau C.M., Mohr L., et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 334:1996;1422-1427
28. Lin S.M., Sheen I.S., Chien R.N., Chu C.M., Liaw Y.F. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 29:1999;971-975
29. Yuen M.F., Hui C.K., Cheng C.C., Wu C.H., Lai Y.P., Lai C.L. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology. 34:2001;139-145
30. Camma C., Giunta M., Andreone P., Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol. 34:2001;593-602
31. Tanaka H., Tsukuma H., Kasahara A., Hayashi N., Yoshihara H., Masuzawa M., et al. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer. 87:2001;741-749
32. Okanoue T., Itoh Y., Minami M., Sakamoto S., Yasui K., Sakamoto M., et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. J Hepatol. 30:1999;653-659
33. Yoshida H., Shiratori Y., Moriyama M., Arakawa Y., Ide T., Sata M., et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med. 131:1999;174-181
34. Trevisani F., D'Intino P.E., Morselli-Labate A.M., Mazzella G., Accogli E., Caraceni P., et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 34:2001;570-575
35. Oka H., Tamori A., Kuroki T., Kobayashi K., Yamamoto S. Prospective study of alpha fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology. 19:1994;61-66
36. Pateron D., Ganne N., Trinchet J.C., Aurousseau M.H., Mal F., Meicler C., et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol. 20:1994;65-71
37. Sherman M., Peltekian K.M., Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology. 22:1995;432-438
38. Ishii M., Gama H., Chida N., Ueno Y., Shinzawa H., Takagi T., et al. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. Am J Gastroenterol. 95:2000;1036-1040
39. Seregni E., Botti C., Bombardieri E. Biochemical characteristics and clinical applications of alpha fetoprotein isoforms. Anticancer Res. 15:1995;1491-1499
40. Taketa K., Endo Y., Sekiya C., Tanikawa K., Koji T., Taga H., et al. A collaborative study for the evaluation of lectin-reactive alpha fetoproteins in early detection of hepatocellular carcinoma. Cancer Res. 53:1993;5419-5423
41. Ajdukiewicz A.B., Kelleher P.C., Krawitt E.L., Walters C.J., Mason P.B., Koff R.S., et al. Alpha fetoprotein glycosylation is abnormal in some hepatocellular carcinoma, including white patients with a normal alpha fetoprotein concentration. Cancer Lett. 74:1993;43-50
42. Khien V.V., Mao H.V., Chinh T.T., Ha P.T., Bang M.H., Lac B.V., et al. Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histology-proven hepatocellular carcinoma. Int J Biol Markers. 16:2001;105-111
43. Oka H., Saito A., Ito K., Kumada T., Satomura S., Kasugai H., et al. Multi-center prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein. J Gastroenterol Hepatol. 16:2001;1378-1383
44. Wang S.S., Lu R.H., Lee F.Y., Chao Y., Huang Y.S., Chen C.C., et al. Utility of lentil lectin affinity of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. J Hepatol. 25:1996;166-171
45. Izuno K., Fujiyama S., Yamasaki K., Sato M., Sato T. Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-gamma-carboxyprothrombin and alpha-fetoprotein: a prospective study. Hepatogastroenterology. 42:1995;387-393
46. Tsai S.L., Huang G.T., Yang P.M., Sheu J.C., Sung J.L., Chen D.S. Plasma des-gamma-carboxyprothrombin in the early stage of hepatocellular carcinoma. Hepatology. 11:1990;481-488
47. Ishizuka H., Nakayama T., Matsuoka S., Gotoh I., Ogawa M., Suzuki K., et al. Prediction of the development of hepatocellular-carcinoma in patients with liver cirrhosis by the serial determinations of serum alpha-L-fucosidase activity. Intern Med. 38:1999;927-931
48. Giardina M.G., Matarazzo M., Morante R., Lucariello A., Varriale A., Guardasole V., et al. Serum alpha-L-fucosidase activity and early detection of hepatocellular carcinoma: a prospective study of patients with cirrhosis. Cancer. 83:1998;2468-2474
49. Marrero J.A., Su G.L., Wei W., Emick D., Conjeevaram H.S., Fontana R.J., et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology. 37:2003;1114-1121
50. Grazi G.L., Mazziotti A., Legnani C., Jovine E., Miniero R., Gallucci A., et al. The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin. Liver Transpl Surg. 1:1995;249-255
51. Tangkijvanich P., Tosukhowong P., Bunyongyod P., Lertmaharit S., Hanvivatvong O., Kullavanijaya P., et al. Alpha-L-fucosidase as a serum marker of hepatocellular carcinoma in Thailand. Southeast Asian J Trop Med Public Health. 30:1999;110-114
52. Zhang B., Yang B. Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer. J Med Screen. 6:1999;108-110
53. Yoshino M. Growth kinetics of hepatocellular carcinoma. Jpn J Clin Oncol. 13:1983;45-52
54. Sheu J.C., Sung J.L., Chen D.S., Yang P.M., Lai M.Y., Lee C.S., et al. Growth rates of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology. 89:1985;259-266
55. Santagostino E., Colombo M., Rivi M., Rumi M.G., Rocino A., Linari S., et al. Six-month versus 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. Blood. 102:2003;78-82
56. Trevisani F., De N.S., Rapaccini G., Farinati F., Benvegnu L., Zoli M., et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol. 97:2002;734-744
57. Ueda K., Matsui O., Kawamori Y., Kadoya M., Yoshikawa J., Gabata T., et al. Differentiation of hyper-vascular hepatic pseudolesions from hepatocellular carcinoma: value of single-level dynamic CT during hepatic arteriography. J Comput Assist Tomogr. 22:1998;703-708
58. Kim T.K., Choi B.I., Han J.K., Chung J.W., Park J.H., Han M.C. Nontumorous arterioportal shunt mimicking hypervascular tumor in cirrhotic liver: two-phase spiral CT findings. Radiology. 208:1998;597-603
59. Yu J.S., Kim K.W., Sung K.B., Lee J.T., Yoo H.S. Small arterial-portal venous shunts: a cause of pseudolesions at hepatic imaging. Radiology. 203:1997;737-742
60. Coakley F.V., Schwartz L.H. Imaging of hepatocellular carcinoma: a practical approach. Semin Oncol. 28:2001;460-473
61. Dodd G.D. III, Miller W.J., Baron R.L., Skolnick M.L., Campbell W.L. Detection of malignant tumors in end-stage cirrhotic livers: efficacy of sonography as a screening technique. Am J Roentgenol. 159:1992;727-733
62. Miller W.J., Baron R.L., Dodd G.D. III, Federle M.P. Malignancies in patients with cirrhosis: CT sensitivity and specificity in 200 consecutive transplant patients. Radiology. 193:1994;645-650
63. Kim S.K., Lim J.H., Lee W.J., Kim S.H., Choi D., Lee S.J., et al. Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic livers: accuracy of helical CT in transplant patients. Am J Roentgenol. 175:2000;693-698
64. Kamura T., Kimura M., Sakai K., Ichida T., Seki H., Yamamoto S., et al. Small hypervascular hepatocellular carcinoma versus hypervascular pseudolesions: differential diagnosis on MRI. Abdom Imaging. 27:2002;315-324
65. Jeong Y.Y., Mitchell D.G., Hann H.W., Malin A.K., Kang H.K., Holland G.A., et al. Small (< 20 mm) enhancing hepatic nodules seen on arterial phase MR imaging of the cirrhotic liver: clinical implications. Am J Roentgenol. 178:2002;1327-1334
66. Oi H., Murakami T., Kim T., Matsushita M., Kishimoto H., Nakamura H. Dynamic MR imaging and early-phase helical CT for detecting small intrahepatic metastases of hepatocellular carcinoma. Am J Roentgenol. 166:1996;369-374
67. Torzilli G., Minagawa M., Takayama T., Inoue K., Hui A.M., Kubota K., et al. Accurate preoperative evaluation of liver mass lesions without fine- needle biopsy. Hepatology. 30:1999;889-893
68. Borzio M., Borzio F., Macchi R., Croce A.M., Bruno S., Ferrari A., et al. The evaluation of fine-needle procedures for the diagnosis of focal liver lesions in cirrhosis. J Hepatol. 20:1994;117
69. Levy I., Greig P.D., Gallinger S., Langer B., Sherman M. Resection of hepatocellular carcinoma without preoperative tumor biopsy. Ann Surg. 234:2001;206-209
70. Shimizu A., Ito K., Koike S., Fujita T., Shimizu K., Matsunaga N. Cirrhosis or chronic hepatitis: evaluation of small (< or = 2-cm) early-enhancing hepatic lesions with serial contrast-enhanced dynamic MR imaging. Radiology. 226:2003;550-555
71. Llovet J.M., Bru C., Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 19:1999;329-338
72. Bruix J., Castells A., Bosch J., Feu F., Fuster J., Garcia-Pagan J.C., et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology. 111:1996;1018-1022
73. Fong Y., Sun R.L., Jarnagin W., Blumgart L.H. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg. 229:1999;790-799
74. Arii S., Yamaoka Y., Futagawa S., Inoue K., Kobayashi K., Kojiro M., et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology. 32:2000;1224-1229
75. Yamamoto J., Okada S., Shimada K., Okusaka T., Yamasaki S., Ueno H., et al. Treatment strategy for small hepatocellular carcinoma: comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatology. 34:2001;707-713
76. Nonami T., Nakao A., Kurokawa T., Inagaki H., Matsushita Y., Sakamoto J., et al. Blood loss and ICG clearance as best prognostic markers of post-hepatectomy liver failure. Hepatogastroenterology. 46:1999;1669-1672
77. Vauthey J.N., Lauwers G.Y., Esnaola N.F., Do K.-A., Belghiti J., Mirza N., et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol. 20:(6):2002;1527-1536
78. Livraghi T., Benedini V., Lazzaroni S., Meloni F., Torzilli G., Vettori C. Long-term results of single-session percutaneous ethanol injection in patients with large hepatocellular carcinoma. Cancer. 83:1998;48-57
79. Livraghi T., Giorgio A., Marin G., Salmi A., de Sio I., Bolondi L., et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology. 197:1995;101-108
80. Livraghi T., Bolondi L., Buscarini L., Cottone M., Mazziotti A., Morabito A., et al. No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Italian Cooperative HCC Study Group. J Hepatol. 22:1995;522-526
81. Livraghi T., Goldberg S.N., Lazzaroni S., Meloni F., Solbiati L., Gazelle G.S. Small hepatocellular carcinoma: treatment with radiofrequency ablation versus ethanol injection. Radiology. 210:1999;655-661
82. Llovet J.M., Vilana R., Bru C., Bianchi L., Salmeron J.M., Boix L., et al. Increased risk of tumour seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology. 33:2001;1124-1129
83. Group d'Etude et de Traitment du Carcinome Hepatocellulaire. A comparison of Lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med. 332:1995;1256-1261
84. Madden M.V., Krige J.E., Bailey S., Beningfield S.J., Geddes C., Werner I.D., et al. Randomised trial of targeted chemotherapy with Lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut. 34:1993;1598-1600
85. Llovet J.M., Real M.I., Montana X., Planas R., Coll S., Aponte J., et al. Arterial immobilization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet. 359:2002;1734-1739
86. Lo C.M., Ngan H., Tso W.K., Liu C.L., Lam C.M., Poon R.T., et al. Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 35:2002;1164-1171
87. Llovet J.M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 37:2003;429-442
88. Yeo W., Chan P.K., Zhong S., Ho W.M., Steinberg J.L., Tam J.S., et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 62:2000;299-307
89. Mazzaferro V., Regalia E., Doci R., Andreola S., Pulvirenti A., Bozzetti F., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 334:1996;693-699
90. Llovet J.M., Fuster J., Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 30:1999;1434-1440
91. Yao F.Y., Ferrell L., Bass N.M., Watson J.J., Bacchetti P., Venook A., et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 33:2001;1394-1403
92. Gondolesi G., Munoz L., Matsumoto C., Fishbein T., Sheiner P., Emre S., et al. Hepatocellular carcinoma: a prime indication for living donor transplantation. J Gastrointest Surg. 6:2002;102-107
93. Oldhafer K.J., Chavan A., Fruhauf N.R., Flemming P., Schlitt H.J., Kubicka S. Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: marked tumor necrosis, but no survival benefit? J Hepatol. 29:1998;953-959
94. Allgaier H.P., Deibert P., Olschewski M., Spamer C., Blum U., Gerok W., et al. Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection - a single-center analysis including 132 patients. Int J Cancer. 79:1998;601-605
95. Llovet J.M., Mas X., Aponte J.J., Fuster J., Navasa M., Christensen E., et al. Cost-effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut. 50:2002;123-128
96. Johnson P. Are there indications for chemotherapy in hepatocellular carcinoma? Surg Clin North Am. 12:2003;127-134